CDNA - CareDx, Inc

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
24.62
+0.73 (+3.06%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close23.89
Open24.13
Bid23.01 x 900
Ask25.34 x 800
Day's Range23.46 - 24.80
52 Week Range5.07 - 30.80
Volume502,524
Avg. Volume744,664
Market Cap1.004B
Beta (3Y Monthly)1.61
PE Ratio (TTM)N/A
EPS (TTM)-2.29
Earnings DateAug 8, 2017 - Aug 14, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est36.25
Trade prices are not sourced from all markets
  • GlobeNewswire10 days ago

    CareDx to Present New AlloSure® Data at American Society of Transplant Surgeons Winter Symposium

    BRISBANE, Calif., Jan. 09, 2019 -- CareDx, Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically.

  • GlobeNewswire12 days ago

    CareDx Reports Preliminary Fourth Quarter and Full Year 2018 Financial Results

    CareDx, Inc. (CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today reported preliminary financial results for the fourth quarter and full year ended December 31, 2018.

  • CareDx Sees Hammer Chart Pattern: Time to Buy?
    Zacks16 days ago

    CareDx Sees Hammer Chart Pattern: Time to Buy?

    CareDx has been struggling lately, but the selling pressure may be coming to an end soon.

  • Best Sector of 2018 and its Hit ETFs & Stocks
    Zacks17 days ago

    Best Sector of 2018 and its Hit ETFs & Stocks

    Healthcare was the best-performing sector of 2018 and we have highlighted top-performing ETFs and stocks from this sector.

  • Does The CareDx, Inc (NASDAQ:CDNA) Share Price Fall With The Market?
    Simply Wall St.17 days ago

    Does The CareDx, Inc (NASDAQ:CDNA) Share Price Fall With The Market?

    Anyone researching CareDx, Inc (NASDAQ:CDNA) might want to consider the historical volatility of the share price. Modern finance theory considers volatility to be a measure of risk, and there are Read More...

  • IBD Stock Of The Day Nears Profitability As Revenue Spikes
    Investor's Business Dailylast month

    IBD Stock Of The Day Nears Profitability As Revenue Spikes

    CareDx is the IBD Stock Of The Day as the diagnostics firm approaches its first quarter in the black amid continuing sales growth. CareDx makes organ transplant tests.

  • GlobeNewswirelast month

    CareDx Director Dr. Amy Abernethy Resigns Board Seat to Become Principal Deputy Commissioner of the FDA

    CareDx, Inc. (CDNA), a leading molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that Dr. Amy Abernethy, a member of its Board of Directors, will step down from the Board effective January 31, 2019 to accept an appointment as Principal Deputy Commissioner of the U.S. Food and Drug Administration (FDA).

  • Do Hedge Funds Love CareDx, Inc. (CDNA)?
    Insider Monkeylast month

    Do Hedge Funds Love CareDx, Inc. (CDNA)?

    Investing in small cap stocks has historically been a way to outperform the market, as small cap companies typically grow faster on average than the blue chips. That outperformance comes with a price, however, as there are occasional periods of higher volatility. The one and a half month time period since the end of the […]

  • GlobeNewswire2 months ago

    New Research: Key Drivers of Growth for Mersana Therapeutics, Maiden, Payment Data, CareDx, Natera, and Spero Therapeutics — Factors of Influence, Major Initiatives and Sustained Production

    NEW YORK, Nov. 28, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • GlobeNewswire2 months ago

    CareDx Strengthens Executive Leadership Team with the Appointment of Reginald Seeto, MB.BS, as President and Chief Business Officer

    CareDx, Inc. (CDNA), a leading molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that Reginald Seeto, MB.BS., has joined the company in the newly created role of President and Chief Business Officer. Dr. Seeto brings 20 years of experience in commercial operations, corporate development and strategy, and executive leadership to CareDx. Before joining CareDx, Dr. Seeto was Chief Operating Officer at Ardelyx leading pre-launch efforts for tenapanor and corporate development, where he completed a series of partnerships.

  • What Kind Of Shareholder Appears On The CareDx Inc’s (NASDAQ:CDNA) Shareholder Register?
    Simply Wall St.2 months ago

    What Kind Of Shareholder Appears On The CareDx Inc’s (NASDAQ:CDNA) Shareholder Register?

    If you want to know who really controls CareDx Inc (NASDAQ:CDNA), then you’ll have to look at the makeup of its share registry. Institutions often own shares in more established Read More...

  • GlobeNewswire2 months ago

    CareDx Announces Full Repayment of its Outstanding Debt

    BRISBANE, Calif., Nov. 26, 2018 -- CareDx, Inc. (NASDAQ: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically.

  • GlobeNewswire2 months ago

    CareDx Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

    CareDx, Inc. (CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced the closing of its previously announced public offering of 2,300,000 of shares of common stock at a public offering price of $24.50 per share, which includes the exercise in full by the underwriters of their option to purchase up to 300,000 additional shares of common stock. The net proceeds to CareDx from the offering are expected to be approximately $52.8 million, after deducting underwriting discounts and commissions and estimated offering expenses. Jefferies and Piper Jaffray acted as joint book-running managers for the offering.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of CDNA earnings conference call or presentation 8-Nov-18 9:30pm GMT

    Q3 2018 CareDx Inc Earnings Call

  • GlobeNewswire2 months ago

    CareDx Announces Proposed Public Offering of Common Stock

    CareDx, Inc. (CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that it intends to offer and sell, subject to market and other conditions, 2,000,000 shares of its common stock in an underwritten public offering. CareDx also expects to grant the underwriters of the offering a 30 day option to purchase up to an additional 300,000 shares of common stock offered in the public offering on the same terms and conditions.  All of the shares will be offered and sold by CareDx. Jefferies and Piper Jaffray are acting as joint book-running managers for the offering.

  • CareDx (CDNA) Reports Q3 Loss, Tops Revenue Estimates
    Zacks2 months ago

    CareDx (CDNA) Reports Q3 Loss, Tops Revenue Estimates

    CareDx (CDNA) delivered earnings and revenue surprises of 50.00% and 14.70%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press2 months ago

    CareDx: 3Q Earnings Snapshot

    The Brisbane, California-based company said it had a loss of 54 cents per share. Losses, adjusted for non-recurring costs and stock option expense, were 1 cent per share. The molecular diagnostics company ...

  • GlobeNewswire2 months ago

    CareDx to Participate in Upcoming Investor Conferences

    BRISBANE, Calif., Nov. 07, 2018 -- CareDx, Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically.

  • Harry Boxer’s four stocks to watch this week
    MarketWatch3 months ago

    Harry Boxer’s four stocks to watch this week

    • Array BioPharma (ARRY) gained $1.16 to $16.20 Wednesday after posting quarterly results that topped Wall Street expectations. The move broke the stock out above key lateral resistance as it has emerged from a head-and-shoulders bottoming pattern. Volume of 6.5 million shares was the biggest for the drug developer since May when its stock last broke out.

  • CareDx (CDNA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
    Zacks3 months ago

    CareDx (CDNA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

    CareDx (CDNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.